arGEN-X (The Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform and potential applications in oncology and infectious disease, closed a $13.8M Series A financing. Participants include Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund and Thuja Capital Healthcare.